NCT00003002View on ClinicalTrials.gov

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 1996

Primary Completion Date

January 31, 2004

Study Completion Date

January 31, 2004

Conditions
Breast CancerLung CancerOvarian Cancer
Interventions
BIOLOGICAL

HER-2/neu peptide vaccine

BIOLOGICAL

sargramostim

Trial Locations (1)

98195

University of Washington School of Medicine, Seattle

All Listed Sponsors
lead

University of Washington

OTHER